Shares of MaxCyte, Inc. (LON:MXCT – Get Free Report) crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of GBX 1.21 and traded as low as GBX 1.20. MaxCyte shares last traded at GBX 1.25, with a volume of 12,670,056 shares traded.
MaxCyte Stock Performance
The stock has a market capitalization of £1.38 million, a price-to-earnings ratio of -0.03 and a beta of 1.13. The company’s fifty day simple moving average is GBX 1.21 and its 200 day simple moving average is GBX 1.10. The company has a quick ratio of 14.38, a current ratio of 10.88 and a debt-to-equity ratio of 8.74.
MaxCyte Company Profile
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions.
Further Reading
- Five stocks we like better than MaxCyte
- Could a Trucking Squeeze Become J.B. Hunt’s Biggest Edge?
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
